Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA195404 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Clonal Evolution in Patients with Chronic Lymphocytic Leukemia
| PRJNA315752 | ENA
Project description:Clonal Evolution in Patients with Chronic Lymphocytic Leukemia
| PRJNA315751 | ENA
Project description:Circulating tumor DNA reflects treatment response and clonal evolution in chronic lymphocytic leukemia
| PRJNA361191 | ENA
Project description:<p>Large-scale whole-exome sequencing (WES) of primary tumor samples enables the unbiased discovery of recurrent putative driver events and patterns of clonal evolution. We report the identification of 44 recurrently mutated genes and 11 recurrent CNVs through the WES of 538 chronic lymphocytic leukemia (CLL) and matched germline DNAs. These include previously unrecognized cancer drivers (e.g., RPS15, IKZF3), and collectively identify nuclear export, MYC activity and MAPK signaling as central pathways affected by somatic mutation in CLL. A clonality analysis of this large dataset further enabled the reconstruction of temporal relationships between these driver events. Several drivers were associated with shorter progression-free survival (PFS) in 280 samples that were collected prior to uniform treatment with front line chemo-immunotherapy, with mature follow up of greater than 10 years. Direct comparison between matched pretreatment and relapse CLL from 59 samples demonstrated marked clonal evolution occurring in more than 95% of these patients. Distinct patterns of clonal evolution in relationship to specific gene alteration were observed, suggesting a hierarchy of fitness amongst mutations. Thus, large WES datasets of clinically informative samples enables the discovery of novel driver genes as well as the network of relationships between the drivers and their impact on disease relapse and clinical outcome.</p>
| phs000922 | dbGaP
Project description:THis is a simple ordinary differential equation model describing chemoimmunotherapy of chronic lymphocytic leukemia, including descriptions of the combinatorial effects of chemotherapy and adoptive cellular immunotherapy.
2024-09-02 | BIOMD0000000879 | BioModels
Project description:Clonal and subclonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). Evolution can work to select not only genetic mutations, but also epigenetic states. Here we performed a long-term longitudinal DNA methylation profiling study of CLL patients to look for associations of epigenetic evolution to different disease courses. In line with the genetic data, large-scale methylation evolution was not present in any of the evaluated long-term untreated (n = 3) and relapsed (n = 2) patients displaying clonal changes of linear type while 3 of the 5 examined refractory patients featured profound changes in DNA methylation.
2021-03-15 | GSE143411 | GEO
Project description:Transcription profiling by array of human chronic lymphocytic leukemia cells after treatment with valproic acid
2025-01-24 | E-GEOD-14973 | ExpressionAtlas
Project description:Transcription profiling by array of human chronic lymphocytic leukemia cells after treatment with LMP-420
2025-01-24 | E-GEOD-20211 | ExpressionAtlas
Project description:Adaptation of Chronic Lymphocytic Leukemia Cells to Ibrutinib Therapy
| PRJNA526453 | ENA
Project description:To define clonal evolution of somatic copy number alterations (CNAs) in chronic lymphocytic leukemia (CLL), sequential samples of 103 individuals were investigated by SNP-array analysis for appearance of novel CNAs. Patients were enrolled on the CLL8 trial and uniformly received fludarabine, cyclophosphamide +/- rituximab (FC/FCR). Comparing two sequential samples prior to therapy (N=27, a median of 2.9 years apart), CNA evolution occurred in 19% of cases. In contrast, when comparing treatment‑initiation and relapse genomic profiles (a median of 3.6 years apart), CNA evolution was seen in 40% of cases. This suggested association of FC(R) treatment with higher rate of CNA evolution. The only clinical feature significantly associated with CNA evolution was FCR therapy compared with FC (OR=2.806, p=0.024). As this might be related to narrower evolutionary bottlenecks imposed by the more effective FCR therapy, which could execute more selection pressure, we examined matched minimal residual disease data. We found CNA evolution more frequently in cases with CLL cell numbers rapidly receding in early phases of treatment. Finally, we observed frequent rises of TP53 mutant/deficient clones with therapy (N=19, 22%) that were associated with decreased overall survival (p=0.016). These results demonstrated that re-examination of TP53 status upon relapse provides important information.
2017-08-25 | GSE83566 | GEO